In the present study, we showed that the silencing OCT1 or NCAPH suppressed the proliferation of MCF-7 and LTED cells, which suggests that OCT1 and NCAPH could be potential targets for breast cancer therapy. This evidence concerns the gene NCAPH and breast carcinoma.